Compare Neurocrine Biosciences Inc (NBIX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Toyota Motor Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Toyota Motor Corp trades at $184.68 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 15.1× Neurocrine Biosciences Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Toyota Motor Corp for 116 Days on average.
| NBIX | TM | |
|---|---|---|
Market Cap | $14.36B | $217.38B |
Volume | 1,237,180 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $248.29 |
52-Week Low | $123.10 | $166.50 |
Typical Hold Time | 23 Days | 116 Days |
Enterprise Value | $14.37B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Toyota Motor trades at $184.84, up 1.06% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while delivering consistent earnings beats. Recent U.S. sales growth and electrification progress contrast with China market challenges and production disruptions from Thailand floods.
Toyota presents a value opportunity with solid profitability and market share gains, though technical weakness and regional sales pressures warrant caution. The company's electrification investments and strong U.S. position support long-term growth, while currency risks and competitive pressures remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
